Chemodex

Melatonin

CHF 34.00
In stock
CDX-M0466-G0055 gCHF 34.00
CDX-M0466-G02525 gCHF 150.00
More Information
Product Details
Synonyms N-Acetyl-5-methoxytryptamine; NSC 56423; NSC 113928; Regulin
Product Type Chemical
Properties
Formula

C13H16N2O2

MW 232.28
CAS 73-31-4
RTECS AC5955000
Purity Chemicals ≥98% (TLC)
Appearance White to off-white powder.
Solubility Soluble in DMSO (20mg/ml), DMF (20mg/ml) or ethanol (10mg/ml).
Identity Determined by 1H-NMR.
Declaration Manufactured by Chemodex.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

InChi Key DRLFMBDRBRZALE-UHFFFAOYSA-N
Smiles CC(NCCC1=CNC2=CC=C(OC)C=C21)=O
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Description

Melatonin is an endogeneous hormone that plays a prominent role in the control of circadian rhythm that displays anti-inflammatory, anti-obesity, anti-cancer, bone-protective, cardiovascular, immunomodulatory, neuroprotective and antipoxidant (free radical scavenging) properties. Melatonin functions as a glycolytic since it inhibits the Warburg effect. Melatonin may have advantages over the synthetic glycolytics since it is an endogenously synthesized molecule in every organism including in the human. Melatonin is also a mitophagy regulator. It seems to exert an essential effect on mitochondrial physiology and facilitates mitochondrial function. A central mechanism by which melatonin protects mitochondria is by restoring the MMP through blocking mPTP opening under stress and activating uncoupling proteins (UCPs) to marginally decrease MMP under normal conditions. Melatonin has also been proposed as an adjuvant in COVID-10 treatment, due to it's anti-inflammatory properties and possible reduction of cytokine storm. Many biological effects of melatonin are transduced through melatonin receptors, including the MT1, MT2, and MT3 subtypes. Melatonin is a full agonist of melatonin receptor 1 (picomolar binding affinity) and melatonin receptor 2 (nanomolar binding affinity), both of which belong to the class of G-protein coupled receptors (GPCRs). Melatonin receptors 1 and 2 are both Gi/o-coupled GPCRs, although melatonin receptor 1 is also Gq-coupled. Melatonin also acts as a high-capacity free radical scavenger within mitochondria which also promotes the expression of antioxidant enzymes such as superoxide dismutase, glutathione peroxidase, glutathione reductase, and catalase via signal transduction through melatonin receptors. Two main mechanisms have been put forward to explain the antioxidant and free radical properties of melatonin, by binding to the MT3 binding site and to the cytosolic enzyme quinone reductase 2 (QR2), and through the scavenging of free radicals, as this hormone has been suggested to be an electron donor. However, there are more than 15 proteins, including receptors (MT1, MT2, Mel1c, CAND2, ROR, VDR), enzymes (QR2, MMP-9, pepsin, PP2A, PR-10 proteins), pores (mtPTP), transporters (PEPT1/2, Glut1), and other proteins (HBS, CaM, tubulin, calreticuline), that have been suggested to interact with melatonin at sub-nanomolar to millimolar melatonin concentrations and could be responsible for some of it's biological properties.

Product References

(1) R.J. Reiter, et al.; Life Sci. 60, 2255 (1997) | (2) R.J. Reiter, et al.; Cell Biochem. Biophys. 34, 237 (2001) | (3) J.A. Boutin, et al.; Trends Pharm. Sci. 26, 412 (2005) | (4) R. Jockers, et al.; Br. J. Pharmacol. 173, 2702 (2016) (Review) | (5) L. Liu, et al.; Front. Endocrinol. 10, 791 (2019) (Review) | (6) R. Zhang, et al.; Life Sci. 250, 117583 (2020) (Review) | (7) D.M. Chitimus, et al.; Biomolecules 10, 1211 (2020) (Review) | (8) N. Ferlazzo, et al.; Antioxidants 5, 1088 (2020) (Review) | (9) C. Rodriquez, et al.; J. Cell Physiol. 236, 27 (2021) (Review) | (10) J. Wu, et al.; Pharmacol. Res. 163, 105279 (2021) (Review) | (11) R.J. Reiter, et al.; Int. J. Mol. Sci. 22, 764 (2021) (Review)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.